Opinion
Video
Author(s):
Panelists discuss how the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) encompasses multiple therapeutic options including novel hormonal agents, chemotherapy, and targeted therapies while highlighting persistent challenges in treatment sequencing, drug resistance, and the need for improved biomarker-driven approaches to optimize patient outcomes.
Video content above is prompted by the following:
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.